CL2016002495A1 - Derivados de piridina macrocíclicos . - Google Patents

Derivados de piridina macrocíclicos .

Info

Publication number
CL2016002495A1
CL2016002495A1 CL2016002495A CL2016002495A CL2016002495A1 CL 2016002495 A1 CL2016002495 A1 CL 2016002495A1 CL 2016002495 A CL2016002495 A CL 2016002495A CL 2016002495 A CL2016002495 A CL 2016002495A CL 2016002495 A1 CL2016002495 A1 CL 2016002495A1
Authority
CL
Chile
Prior art keywords
pyridine derivatives
macrocyclic
macrocyclic pyridine
macrociclycles
ef2k
Prior art date
Application number
CL2016002495A
Other languages
English (en)
Inventor
Berthold Wroblowski
Lieven Meerpoel
Gaston Stanislas Marcella Diels
Bruno Choentjes
Matthias Luc Aimé Versele
Didier Jean-Claude Berthelot
Marc Willems
Marcel Viellevoye
Francois Maria Sommen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2016002495A1 publication Critical patent/CL2016002495A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>COMPUESTOS DERIVADOS DE PIRIDINA MACROCICLICLAS, INHIBIDORES DE EF2K Y Vps34; COMPOSICION FARMACEUTICA; Y SU USO PARA EL TRATAMIENTO DE UNA ENFERMEDAD O UN ESTADO SELECCIONADO DE CANCER, DEPRESION Y TRATORNOS DEL APRENDIZAJE Y LA MEMORIA- </p>
CL2016002495A 2014-04-03 2016-09-30 Derivados de piridina macrocíclicos . CL2016002495A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14163442 2014-04-03
EP14183823 2014-09-05

Publications (1)

Publication Number Publication Date
CL2016002495A1 true CL2016002495A1 (es) 2017-02-24

Family

ID=52781118

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002495A CL2016002495A1 (es) 2014-04-03 2016-09-30 Derivados de piridina macrocíclicos .

Country Status (22)

Country Link
US (1) US20170022201A1 (es)
EP (1) EP3126365B1 (es)
JP (1) JP6420362B2 (es)
KR (1) KR102390274B1 (es)
CN (1) CN106132964B (es)
AU (1) AU2015239100B2 (es)
BR (1) BR112016022700B1 (es)
CA (1) CA2942751C (es)
CL (1) CL2016002495A1 (es)
EA (1) EA029758B1 (es)
ES (1) ES2665797T3 (es)
IL (1) IL248001B (es)
MA (1) MA39823A (es)
MX (1) MX369799B (es)
MY (1) MY185500A (es)
NZ (1) NZ725406A (es)
PE (1) PE20161365A1 (es)
PH (1) PH12016501962A1 (es)
SG (1) SG11201608241UA (es)
UA (1) UA118120C2 (es)
WO (1) WO2015150557A1 (es)
ZA (1) ZA201606768B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10407442B2 (en) 2015-09-24 2019-09-10 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
PT3416945T (pt) 2016-02-19 2020-09-11 Sprint Bioscience Ab Compostos de 6-aril-4-(morfolin-4-il)-1h-piridina-2-ona úteis para o tratamento do cancro e da diabetes
WO2017140843A1 (en) 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP3589627A4 (en) * 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V) (BETA-6) -INTEGRIN
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
PL3601253T3 (pl) 2017-03-28 2022-01-17 Bayer Aktiengesellschaft Nowe hamujące ptefb związki makrocykliczne
EP3642399A4 (en) * 2017-06-22 2020-10-14 Cyclenium Pharma Inc. LIBRARIES OF MACROCYCLIC COMPOUNDS CONTAINING PYRIDINE AND THEIR PREPARATION AND USE PROCEDURES
CN116589462A (zh) 2017-08-23 2023-08-15 思普瑞特生物科学公司 氮杂吲哚基吡啶酮化合物和二氮杂吲哚基吡啶酮化合物
HUE058661T2 (hu) 2017-08-23 2022-09-28 Sprint Bioscience Ab Morfolinilpiridon vegyületek
EP3672948B1 (en) 2017-08-23 2022-10-05 Sprint Bioscience AB Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
HRP20220571T1 (hr) 2017-08-23 2022-06-10 Sprint Bioscience Ab Spoj piridilpiridona
PE20211640A1 (es) 2018-08-29 2021-08-24 Morphic Therapeutic Inc INHIBICION DE LA INTEGRINA xvß6
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001227755A1 (en) * 2000-01-12 2001-07-24 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
US7151096B2 (en) * 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
EP1697384B1 (en) 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
MXPA06007018A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolino con actividad anti-proliferativa.
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
JO3088B1 (ar) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
JP5345388B2 (ja) 2005-06-30 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 環式アニリノ−ピリジノトリアジン
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives
ES2435454T3 (es) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
EP2185562B1 (en) 2007-07-27 2015-12-02 Janssen Pharmaceutica, N.V. Pyrrolopyrimidines useful for the treatment of proliferative diseases
CA2716079C (en) * 2008-03-10 2018-01-16 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors
AU2009256574A1 (en) 2008-06-13 2009-12-17 Novartis Ag 2,4'-bipyridinyl compounds as protein kinase D inhibitors useful for the treatment of IA heart failure and cancer

Also Published As

Publication number Publication date
CA2942751A1 (en) 2015-10-08
US20170022201A1 (en) 2017-01-26
CA2942751C (en) 2023-03-21
BR112016022700A2 (es) 2017-08-15
KR102390274B9 (ko) 2023-03-03
EP3126365A1 (en) 2017-02-08
KR102390274B1 (ko) 2022-04-22
BR112016022700B1 (pt) 2022-01-11
PE20161365A1 (es) 2016-12-17
KR20160140739A (ko) 2016-12-07
PH12016501962B1 (en) 2017-01-09
AU2015239100A1 (en) 2016-09-29
SG11201608241UA (en) 2016-10-28
ZA201606768B (en) 2018-11-28
CN106132964A (zh) 2016-11-16
PH12016501962A1 (en) 2017-01-09
MY185500A (en) 2021-05-19
IL248001B (en) 2018-11-29
MX369799B (es) 2019-11-21
NZ725406A (en) 2022-08-26
MX2016012994A (es) 2016-12-07
CN106132964B (zh) 2019-07-19
ES2665797T3 (es) 2018-04-27
WO2015150557A1 (en) 2015-10-08
MA39823A (fr) 2018-01-09
EA201692000A1 (ru) 2017-01-30
UA118120C2 (uk) 2018-11-26
JP6420362B2 (ja) 2018-11-07
JP2017509685A (ja) 2017-04-06
EP3126365B1 (en) 2018-01-10
AU2015239100B2 (en) 2019-06-27
EA029758B1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
CL2016002495A1 (es) Derivados de piridina macrocíclicos .
CO2017010890A2 (es) Derivados de maitansinoide, conjugados del mismo, y metodos de uso
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016002382A1 (es) Derivados de quinoxalina útiles como moduladores de fgfr quinasa
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
BR112018011133A2 (pt) alvos terapêuticos para a correção do gene humano de distrofina por edição de gene e métodos de uso
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico